Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

Predicting Response to Bladder Cancer Treatment With COXEN Analysis

News

Can Artificial Intelligence–Based Tool Help to Assess Treatment Response in Bladder Cancer?

Medical Literature

TRIM38/GLUT1 Axis May Promote Bladder Cancer Tumorigenesis

News

Trial of Intravesicular Adenovirus Vector Therapy in Bladder Cancer Unresponsive to BCG

News

AACR 2022: KEYNOTE-992 to Study Pembrolizumab Plus Chemoradiotherapy for Bladder Cancer

Medical Literature

Evaluating the Risk of BK Polyomavirus Infection During Childhood and Future Bladder Cancer

News

AACR 2022: Phase II Trial of Pembrolizumab Combined With Oncolytic Vaccine in Bladder Cancer

Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

Thomas W. Flaig, MD, on Choosing Among Many New Bladder Cancer Treatment Options

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

Anti–PD-L1 Therapy With PARP Inhibitor Focus of Phase II Trial in Urothelial Cancer

AACR 2022: Use of Novel Tissue Assays to Predict Therapeutic Response in Bladder Cancer

How Does STAG2 Promote Invasion of Muscle-Invasive Bladder Cancer?

ASCO GU 2022: Use of Gene-Expression Model to Predict Survival Outcomes in Bladder Cancer

Double Antibody-Drug Conjugate Trial Enrolling in Metastatic Bladder Cancer

AACR 2022: Prognostic Value of Cathepsin L in Urinary Bladder Cancer

Evaluating Adjuvant Infigratinib in Bladder Cancer With FGFR3 Alterations

Is Ferroptosis Associated With Bladder Cancer?

View More

Advertisement

Published

Medical Literature

Does a Family History of Any Cancer Increase the Risk for Bladder Cancer?

Is Dietary Acrylamide Intake Associated With the Development of Bladder Cancer?

Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?

View More

Ongoing

CE Activities

Data-driven Debates on the Evolving Bladder Cancer Landscape: Harnessing Novelty to Improve Outcomes

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Bladder Cancer

What's New for GU: Individualizing Genitourinary Cancer Treatment

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

View More

Available

Clinical Trials

Evaluating Cystectomy with Perioperative Pembrolizumab and Perioperative Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.